Company intelligence / Profile preview

StethoMe

Ownership: Private
Development stage: Other

Overview

StethoMe's smart stethoscope and AI platform are CE-marked Class IIa medical devices in the EU. The solution enables at-home monitoring of lung and heart sounds with high accuracy. It has been recommended by leading Polish pediatric societies for asthma management in children. Clinical validation supports its ability to detect abnormal respiratory sounds such as wheezes and crackles; FDA approval process ongoing for US market entry.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: DeviceArtificial intelligence algorithm
Industry: Physiological Monitoring

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on StethoMe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StethoMe.

Explore the full profile